Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01031667
Other study ID # 4-2009-0489
Secondary ID
Status Completed
Phase Phase 4
First received December 11, 2009
Last updated June 16, 2011
Start date November 2009
Est. completion date June 2011

Study information

Verified date June 2011
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of combination therapy with cilostazol and probucol on plaque volume and composition change in comparison with cilostazol alone by serial intravascular ultrasound and virtual histology.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Patients treated with PCI with stent

2. Male or female over 20 years of age

3. Presence of at least one PCI target lesion(lesion length =26mm) with =50% diameter stenosis that can be covered with a single Endeavor Sprint stent(Medtronic)

4. Other PCI target lesions also should be treated with Endeavor Sprint stents

5. Presence of an intermediate non-PCI target lesion with luminal narrowing of =30% and =70% by visual estimation

6. Signed written informed consent to participate in the study

Exclusion Criteria:

1. Intermediate (non-PCI target) lesions that might provide difficulty for IVUS evaluation because of following reasons: heavy calcification (>90° Arc), tortuous vessel with sever angulation, total occlusion, or bifurcation lesions

2. Previous PCI in the last 6 months

3. Previous CABG

4. Patients with AMI undergoing primary PCI or rescue PCI after thrombolysis

5. Cardiogenic shock

6. Inability to take adequate anti-platelet therapy

7. Thrombocytopenia (platelet count <70 x 109/l)

8. Known hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, cilostazol, probucol, statin, contrast media*

*Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.

9. History of severe ventricular arrhythmia

10. Significant QTc prolongation (=470 ms) on ECG

11. NYHA class III/IV heart failure or LV ejection fraction =35%

12. Familial hypercholesterolemia

13. Uncontrolled hypertriglyceridemia (>400 mg/dL)

14. Chronic renal failure with serum creatinine level =2mg/dL

15. Severe liver disease or transaminase level =3 times the upper limit of normal.

16. Pregnant or breastfeeding

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cilostazol, Probucol / placebo of probucol
An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.

Locations

Country Name City State
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul

Sponsors (2)

Lead Sponsor Collaborator
Yonsei University Korea Otsuka Pharmaceutical Co.,Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plaque volume change of the index lesion with intermediate stenosis(non-PCI target lesion) From February 01, 2009 to July 31, 2011 No
See also
  Status Clinical Trial Phase
Completed NCT03650543 - Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication Phase 4
Recruiting NCT05788861 - Invasive Group A Streptococcal Infection
Completed NCT03712748 - Online Imaginal Exposure N/A
Recruiting NCT00226408 - Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Phase 3
Completed NCT05104957 - Evaluation of the Kinesiology Taping Effectiveness in the Treatment of Lumbar Spine Pain N/A
Recruiting NCT06137053 - Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
Completed NCT01023126 - Obesity and Psychotherapy as an Alternative to Treatment N/A
Not yet recruiting NCT06413407 - Tai Chi Exercise and Receptive Music Therapy for the Elderly N/A
Recruiting NCT06040515 - Probiotic After Acute Colonic Diverticulitis
Recruiting NCT05340738 - AI-Based Fidelity Feedback to Enhance CBT N/A
Active, not recruiting NCT02455609 - Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain Phase 2/Phase 3
Completed NCT05261503 - Investigation of the Effectiveness of Environmental Enrichment-Based Intervention in Preterm Infants N/A
Completed NCT04926311 - Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder
Recruiting NCT03721783 - Infant and Child European Cryoablation Project ICECaP
Recruiting NCT03283839 - Consequences of Temporomandibular Disorder on Balance Control N/A
Recruiting NCT05901558 - Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD N/A
Completed NCT03177863 - Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age N/A
Recruiting NCT06146972 - Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis Phase 4
Recruiting NCT03161249 - Psychoeducative Treatment of FEP With Mobile Training N/A
Recruiting NCT04490317 - CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)